Gaurav D. Shah, M.D., is the Chief Executive Officer at Rocket Pharmaceuticals Inc., a leading biotechnology company focused on developing gene therapies for rare and devastating diseases. Dr. Shah joined Rocket Pharmaceuticals in 2018, bringing with him a wealth of experience in the biopharmaceutical industry. Prior to his current role, he served as the Chief Medical Officer at Aelix Therapeutics, where he played a pivotal role in advancing the company's HIV immunotherapy program. Dr. Shah also held key positions at Novartis, where he contributed to the development and commercialization of several successful oncology and cardiovascular products. Under Dr. Shah's leadership, Rocket Pharmaceuticals has made significant strides in advancing its pipeline of gene therapies. One of the company's notable achievements during his tenure is the successful completion of a Phase 1 clinical trial for its lead candidate, RP-L102, a lentiviral vector-based gene therapy for Fanconi anemia. Dr. Shah's strategic vision and dedication to patients have been instrumental in guiding the company through the complex process of bringing innovative therapies from the lab to the clinic. His expertise in clinical development and regulatory affairs has been crucial in navigating the challenges associated with developing novel gene therapies. As CEO, Dr. Shah continues to drive Rocket Pharmaceuticals' mission to transform the lives of patients with rare genetic disorders. He oversees the company's operations, strategic planning, and partnerships, ensuring that Rocket remains at the forefront of the gene therapy field. Dr. Shah's commitment to scientific excellence and patient-centric approach have earned him recognition as a respected leader in the biotechnology industry. With his guidance, Rocket Pharmaceuticals is well-positioned to deliver life-changing therapies to patients in need.